332.50p+0.00 (+0.00%)13 May 2021, 15:54
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Faron Pharmaceuticals Oy Fundamentals

Company NameFaron Pharmaceuticals OyLast Updated2021-05-13
Shares in Issue50.458 mMarket Cap£167.77 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-€0.37EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.3854Debt Equity Ratio0
Asset Equity Ratio-4.5251Cash Equity Ratio-2.2217
Quick Ratio0.8122Current Ratio1.13
Price To Book Value0ROCE0

Faron Pharmaceuticals Oy Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Faron Pharmaceuticals Oy Company Financials

Tangible Assets€375,000.00€399,000.00€17,000.00
Intangible Assets€565,000.00€529,000.00€525,000.00
Total Fixed Assets€996,000.00€1.00 m€1.18 m
Debtors€1.17 m€955,000.00€596,000.00
Cash & Equivalents€4.11 m€7.06 m€4.07 m
Other Assets000
Total Assets€8.37 m€10.21 m€8.00 m
Creditors within 1 year€6.50 m€6.08 m€5.75 m
Creditors after 1 year€3.71 m€2.52 m€1.89 m
Other Liabilities000
Total Liabilities€10.22 m€8.60 m€7.63 m
Net assets-€1.85 m€1.61 m€369,000.00
Called up share capital€2.69 m€2.69 m€2.69 m
Share Premium000
Profit / Loss-€16.94 m-€13.25 m-€20.08 m
Other Equity-€1.85 m€1.61 m€369,000.00
Preference & Minorities000
Total Capital Employed-€1.85 m€1.61 m€369,000.00
Debt Ratio0€0.61€0.84
Assets / Equity-4.5251-4.5251-4.5251
Cash / Equity-2.2217-2.2217-2.2217
Cash Flow202020192018
Cash from operating activities-€17.48 m-€11.52 m-€20.52 m
Cashflow before financing-€2.69 m€3.08 m-€4.98 m
Increase in Cash-€2.83 m€2.98 m-€5.28 m
Cost of sales000
Gross Profit000
Operating Profit-€16.65 m-€13.10 m-€19.99 m
Pre-Tax profit-€16.94 m-€13.25 m-€20.08 m

Faron Pharmaceuticals Oy Company Background

ActivitiesFaron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested in several Phase III studies around the world against COVID-19.
Latest Interim Date24 Sep 2020
Latest Fiscal Year End Date25 Mar 2021

Faron Pharmaceuticals Oy Directors

2021-04-29Dr. Gregory B. Brown,M.D.Non-Executive Director
2021-04-29Dr. Frank Murdoch ArmstrongNon-Executive Director,Chairman
2018-09-13Dr. Huaizheng PengNon-Executive Director
2018-09-13Dr. Jonathan Kenneth Charles KnowlesNon-Executive Director
2021-04-29Mr. Matti Esa MannerNon-Executive Director,Vice Chairman
2021-04-29Ms. Anne Michelle Clem WhitakerNon-Executive Director
2021-04-29Mr. Leopoldo Giampaolo ZambelettiNon-Executive Director
2021-04-29Dr. Markku Tapani JalkanenExecutive Director,Chief Executive Officer
2019-05-31Mr. Yrjo Erik Kristian WichmannExecutive Director,Chief Financial Officer
2019-11-08Mr. Juho Markku JalkanenNon-Executive Director
2021-04-29Mr. John PoulosNon-Executive Director
2021-04-07Mr. Toni HanninenExecutive Director,Chief Financial Officer

Faron Pharmaceuticals Oy Contact Details

Company NameFaron Pharmaceuticals Oy
AddressJoukahaisenkatu 6, Intelligate, Turku, FI-20520
Telephone+358 24695151

Faron Pharmaceuticals Oy Advisors

Financial PR AdviserConsilium Strategic Communications
Phone+44 2037095700
Financial PR AdviserWestwicke Partners
Phone+1 339 970-2843
StockbrokerPanmure Gordon (UK) Ltd
Phone+44 2078862500
SolicitorJones Day
Phone+44 2070395959
Fax+44 2070395999
Phone+358 9 22 800
Fax+358 9 174 102
SolicitorHannes Snellman
Nominated AdviserCairn Financial Advisers LLP
Phone+44 2072130880
StockbrokerWhitman Howard
Phone+44 2076591234